Nucleic acids encoding anti-CD40 antibodies

Patent metadata

Field	Value
Publication number	US-11267895-B2
Application number	US-202016946302-A
Country	US
Kind code	B2
Filing date	Jun 15, 2020
Priority date	Mar 10, 2009
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

First claim

What is claimed is:

1. One or more isolated nucleic acid(s) encoding a humanized recombinant antibody or an antigen binding fragment thereof, both of which bind to CD40, comprising CDR1L, CDR2L, and CDR3L from SEQ ID NO:2 and CDR1H, CDR2H, and CDR3H from SEQ ID NO:1.

2. An expression vector comprising the nucleic acid sequence of claim 1 , operably linked to control sequences recognized by a host cell transfected with the vector.

3. A host cell comprising the vector of claim 2 .

4. A method of producing a polypeptide, comprising culturing the host cell of claim 3 under conditions wherein the nucleic acid sequence is expressed, thereby producing the polypeptide, and recovering the polypeptide from the host cell.

5. An isolated nucleic acid sequence encoding a heavy chain variable region comprising CDR1H, CDR2H, and CDR3H from SEQ ID NO:1; or a light chain variable region comprising CDR1L, CDR2L, and CDR3L from SEQ ID NO: 2.

6. One or more isolated nucleic acid(s) encoding a humanized recombinant antibody or an antigen binding fragment thereof, both of which bind to CD40, comprising CDR1L, CDR2L, and CDR3L from SEQ ID NO:7 and CDR1H, CDR2H, and CDR3H from SEQ ID NO:6.

7. An expression vector comprising the nucleic acid sequence(s) of claim 6 , operably linked to control sequences recognized by a host cell transfected with the vector.

8. A host cell comprising the vector of claim 7 .

9. A method of producing a polypeptide, comprising culturing the host cell of claim 8 under conditions wherein the nucleic acid sequence is expressed, thereby producing the polypeptide, and recovering the polypeptide from the host cell.

10. The nucleic acid of claim 1 , wherein the binding fragment is an antibody fragment selected from Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′)2, and a diabody.

11. The nucleic acid of claim 6 , wherein the binding fragment is an antibody fragment selected from Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′)2, and a diabody.

12. The cell of claim 3 , wherein the cell is a bacterial, fungal, insect, or mammalian cell.

13. The cell of claim 8 , wherein the cell is a bacterial, fungal, insect, or mammalian cell.

Assignees

• Baylor Res Institute

Inventors

• Banchereau Jacques F
• Zurawski Gerard
• Zurawski Sandra
• Oh Sangkon

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• C07K16/2878 Primary

  against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• C07K2317/626

  Diabody or triabody · CPC title